{
  "extraction_metadata": {
    "timestamp": "2025-10-02T17:05:42.943799",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 8,
    "total_picos": 31,
    "temperature": 0.1
  },
  "picos_by_country": {
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Docetaxel",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Pemetrexed",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Nivolumab",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Pembrolizumab",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Atezolizumab",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Docetaxel in combination with nintedanib",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Afatinib",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Pemetrexed",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Erlotinib",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Docetaxel",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Docetaxel in combination with ramucirumab",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Docetaxel in combination with nintedanib",
          "Outcomes": ""
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Vinorelbine",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 5795
    },
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "adults with advanced NSCLC with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel monotherapy",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 5598
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": ""
        },
        {
          "Population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel plus nintedanib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 5088
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell bronchial cancer (NSCBC) with the KRAS G12C mutation, whose disease has progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced non-small cell bronchial cancer (NSCBC) with the KRAS G12C mutation, whose disease has progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "chemotherapy",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced non-small cell bronchial cancer (NSCBC) with the KRAS G12C mutation, whose disease has progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "immunotherapy",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 6457
    },
    "IT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IT",
      "PICOs": [],
      "ChunksUsed": 5,
      "ContextTokens": 1715
    },
    "PO": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with a KRas g12c mutation who have experienced disease progression after at least one line of previous use",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with a KRas g12c mutation who have experienced disease progression after at least one line of previous use",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nintedanib in combination with docetaxel",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with a KRas g12c mutation who have experienced disease progression after at least one line of previous use",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 5367
    },
    "PT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel + nintedanib",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "platinum doublet",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 5188
    },
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, in case of progression after at least one previous line of systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation who have progressed after at least one prior line of systemic therapy and who have been treated with docetaxel or who are not medically suitable for treatment with Docetaxel",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 4524
    }
  }
}